Overview

Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to describe the effect of optimized retreatment with bortezomib in combination with dexamethasone followed by prolonged therapy with bortezomib, versus standard retreatment with bortezomib in combination with dexamethasone on progression free survival (PFS).
Phase:
Phase 3
Details
Lead Sponsor:
Janssen-Cilag International NV
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate